



## MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

### Medical Policy

## Intracavitary Balloon Catheter Brain Brachytherapy for Malignant Gliomas or Metastasis to the Brain

### Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

### Policy Number: 602

BCBSA Reference Number: 8.01.45

NCD/LCD: NA

### Related Policies

None

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Intracavitary balloon catheter brain brachytherapy is **INVESTIGATIONAL**, alone or as part of a multimodality treatment regimen, for:

- Primary or recurrent malignant brain tumors, or
- Metastasis to the brain from primary solid tumors outside the brain.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This is <b>not</b> a covered service.
Commercial PPO and Indemnity	This is <b>not</b> a covered service.
Medicare HMO Blue <sup>SM</sup>	This is <b>not</b> a covered service.
Medicare PPO Blue <sup>SM</sup>	This is <b>not</b> a covered service.

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

### CPT Codes

There is no specific CPT code for this service.

## Description

### BRAIN TUMORS

#### Malignant Gliomas

Diffuse fibrillary astrocytoma is the most common glial brain tumor in adults. It is classified histologically into 3 grades: grade II astrocytoma, grade III anaplastic astrocytoma, and grade IV glioblastoma multiforme. Oligodendrogliomas are diffuse neoplasms closely related to diffuse fibrillary astrocytomas clinically and biologically. However, these tumors generally have better prognoses than diffuse astrocytomas, with mean survival times of 10 years vs 2 to 3 years. Also, oligodendrogliomas apparently are more chemosensitive than astrocytomas. The most aggressive and chemoresistant astrocytoma, glioblastoma multiforme has survival times of less than 2 years for most patients.

#### Treatment

Treatment of primary brain tumors begins with surgery with curative intent or optimal tumor debulking, usually followed by radiotherapy and/or chemotherapy. Survival after chemoradiotherapy largely depends on the extent of residual tumor after surgery. Therefore, tumors arising in the midline, basal ganglia, or corpus callosum or those arising in the eloquent speech or motor areas of the cortex have a particularly poor outcome, because they typically cannot be extensively resected. Recurrence is common after surgery for malignant gliomas, even if followed by chemoradiotherapy because the tumors are usually diffusely infiltrating and develop resistance to chemotherapy; also, neurotoxicity limits cumulative doses of whole-brain radiation. Chemotherapy regimens for gliomas usually rely on nitrosourea alkylating agents (carmustine or lomustine), temozolomide, procarbazine, vincristine, and platinum-based agents. The most common regimen combines procarbazine, lomustine, vincristine, and single or multiagent therapy with temozolomide. A biodegradable polymer wafer impregnated with carmustine (Gliadel® Wafer; Guilford Pharmaceuticals) also can be implanted into the surgical cavity as an adjunct to surgery and radiation. It is indicated for newly diagnosed high-grade malignant glioma and for recurrent glioblastoma multiforme.

#### Brain Metastasis From Other Primary Malignancies

Intracranial metastases are a frequent occurrence seen at autopsy in 10% to 30% of deaths from cancer. Lung cancer is the most common source of brain metastasis (relative prevalence, 48%), followed by breast cancer (15%), unknown primary (12%), melanoma (9%), and colon cancer (5%).

#### Treatment

Treatment goals in these patients include local control of existing metastases, regional control to prevent the growth of undetected metastases, extending the duration of overall survival, and maintaining quality of life. Surgical resection followed by whole-brain radiotherapy (WBRT) is the mainstay of treatment for patients with 1 to 3 operable brain metastases and with adequate performance status and control of extracranial disease. Resection plus WBRT extends the duration of survival compared with biopsy plus WBRT. Although adding WBRT to resection does not increase the duration of overall survival, it reduces local and distant recurrence of brain metastases. Thus, WBRT decreases the incidence of death from neurologic causes and may help maintain an adequate quality of life, if the cumulative dose does not cause unacceptable neurotoxicity.

## **INTRACAVITARY BALLOON CATHETER BRAIN BRACHYTHERAPY**

Intracavitary balloon catheter brain brachytherapy is localized temporary high-dose radiotherapy in the brain that requires placement of an inflatable balloon catheter in the surgical cavity, before closing the craniotomy of a resection to remove or debulk a malignant brain mass. A radiation source is then placed in the balloon to expose surrounding brain tissue to radiation, either continuously or in a series of brief treatments. After the patient completes therapy, the radiation source is permanently removed, and the balloon catheter is surgically explanted.

### **Safety Considerations**

Overall, adverse events with GliaSite do not differ greatly from those observed with other brain brachytherapy techniques; however, Adkison et al (2008) reported a case in which linens of a patient with the GliaSite implant were contaminated with radiation. Recovery studies confirmed that systemic absorption is greater than anticipated. Adkison et al concluded that precaution with a Foley catheter should be taken in patients with urinary incontinence. Gerber et al (2007) reported cases of brain hemorrhage have, suggesting the need for careful coagulation control.

### **Summary**

For individuals who have primary newly diagnosed or recurrent brain tumors who receive intracavitary balloon catheter brain brachytherapy as an adjunct to resection, the evidence includes early-phase feasibility and dose-ranging studies, case series, and a retrospective review. Relevant outcomes are overall survival, symptoms, and treatment-related morbidity. The evidence is limited by the lack of RCTs and comparators in nonrandomized studies. The heterogeneity of tumor metastatic tumor types limits the interpretation of reported short-term survival outcomes. Long-term outcome studies have not been reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have metastases to the brain from other tumors who receive intracavitary balloon catheter brain brachytherapy as an adjunct to resection, the evidence includes a multicenter, nonrandomized, single-arm study. Relevant outcomes are overall survival, symptoms, and treatment-related morbidity. The evidence is limited by the lack of RCTs or comparators in nonrandomized studies. The only outcomes data reported have been the local control rates at 1 year. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Policy History**

<b>Date</b>	<b>Action</b>
9/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
9/2017	New references added from BCBSA National medical policy.
7/2014	New references added from BCBSA National medical policy.
6/2013	New references from BCBSA National medical policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
1/1/2012	New policy, effective 1/1/2012, describing ongoing non-coverage.

### **Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Adkison JB, Thomadsen B, Howard SP. Systemic iodine 125 activity after GliSite brachytherapy: safety considerations. *Brachytherapy*. Jan-Mar 2008;7(1):43-46. PMID 18201938
2. Gerber DE, Grossman SA, Chan TA, et al. Intracranial hemorrhage during GliSite RTS manipulation in an anticoagulated patient. *J Radiother Pract*. Jan 2007;6:53-57. PMID 19173012
3. Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. *Am Fam Physician*. Feb 1 2016;93(3):211-217. PMID 26926614
4. National Brain Tumor Society. Quick Brain Tumor Facts. n.d.; <http://braintumor.org/brain-tumor-information/brain-tumor-facts/>. Accessed June 13, 2018.
5. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. *J Neurosurg*. Aug 2003;99(2):297-303. PMID 12924704
6. Gabayan AJ, Green SB, Sanan A, et al. GliSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. *Neurosurgery*. Apr 2006;58(4):701-709; discussion 701-709. PMID 16575334
7. Wernicke AG, Sherr DL, Schwartz TH, et al. The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. *Brachytherapy*. Jan-Mar 2010;9(1):91-99. PMID 19850535
8. Wernicke AG, Sherr DL, Schwartz TH, et al. Feasibility and safety of GliSite brachytherapy in treatment of CNS tumors following neurosurgical resection. *J Cancer Res Ther*. Jan-Mar 2010;6(1):65-74. PMID 20479550
9. Gobitti C, Borsatti E, Arcicasa M, et al. Treatment of recurrent high-grade gliomas with GliSite brachytherapy: a prospective mono-institutional Italian experience. *Tumori*. Sep-Oct 2011;97(5):614-619. PMID 22158493
10. Johannesen TB, Watne K, Lote K, et al. Intracavity fractionated balloon brachytherapy in glioblastoma. *Acta Neurochir (Wien)*. Apr 1999;141(2):127-133. PMID 10189493
11. Welsh J, Sanan A, Gabayan AJ, et al. GliSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. *Int J Radiat Oncol Biol Phys*. May 1 2007;68(1):159-165. PMID 17331666
12. Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliSite brachytherapy. *Int J Radiat Oncol Biol Phys*. Jul 15 2005;62(4):1133-1139. PMID 15990019
13. Waters JD, Rose B, Gonda DD, et al. Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. *J Neurooncol*. Jul 2013;113(3):467-477. PMID 23673513
14. Rogers LR, Rock JP, Sills AK, et al. Results of a phase II trial of the GliSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. *J Neurosurg*. Sep 2006;105(3):375-384. PMID 16961129
15. Barker FG, 2nd. Brain metastasis [editorial]. *J Neurosurg*. Sep 2006;105(3):371-372; discussion 372-374. PMID 16961128
16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/cns.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf). Accessed June 13, 2018.